| Customization: | Available |
|---|---|
| Dosage Form: | Injection |
| Dossier: | Ready |
|
Still deciding? Get samples of US$ 0.1/Piece
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Generic Name | Ondansetron Injection 8mg/4ml |
| Strength | 8mg/4ml |
| Packing | 5amps/box |
| Origin | China |
This product is colorless or almost colorless clear liquid.
For vomiting caused by radiation therapy and cytotoxic chemotherapy.
Usage and dosage:
1. For vomiting caused by highly emetic chemotherapeutic drugs: Ondansetron hydrochloride injection 8mg was injected intravenously 15 minutes before chemotherapy, 4 hours after chemotherapy, and 8 hours after chemotherapy, Ondansetron hydrochloride tablet 8mg was taken orally every 8 hours after chemotherapy was stopped for 5 days.
2. For vomiting caused by chemotherapy drugs that are not very strong in emetic degree, Ondansetron hydrochloride injection 8mg intravenously 15 minutes before chemotherapy, and Ondansetron hydrochloride tablets 8mg orally every 8 hours thereafter for 5 days.
3. For radiotherapy induced vomiting: The first dose should be taken orally with 8mg tablets 1-2 hours before radiotherapy, followed by 8mg ondansetron hydrochloride tablets every 8 hours, depending on the duration of radiotherapy.
Matters needing attention:
There is no need to adjust the dosage, frequency and route of administration for patients with kidney damage. For patients with liver function impairment, patients with moderate or severe liver function impairment have a significantly reduced ability to clear this product, and the serum half-life is also significantly prolonged. Therefore, the dosage should not exceed 8mg per day; This product should not be used after abdominal surgery to avoid covering up the symptoms of ileal or gastric dilation; This injection and the ampoule or syringe containing this product do not contain preservatives, can only be used once after opening, any remaining solution should be discarded; The compatibility of this product with polyvinyl chloride infusion bag and polyvinyl chloride drug delivery device was studied, and it was found that this product also had considerable stability when using polyethylene infusion bag or type I glass bottle. Ondansetron diluent diluted with 0.9%W/V sodium chloride or 5%w/v glucose was stable in a polypropylene glycol ester syringe, so it was considered stable when mixed with other compatible infusion fluids in a polypropylene glycol ester syringe. Ampoules of this product cannot be sterilized under high pressure.
){kind=link}